Group 1 - The company plans to globally offer 33.44 million shares, with 3.34 million shares available in Hong Kong and 30.10 million shares for international offering [1] - The subscription period is from July 31 to August 5, with a maximum offer price of HKD 15.50 per share and an entry fee of approximately HKD 3,131.26 for 200 shares [1] - The total expected fundraising amount is HKD 475 million, with a net amount of HKD 421 million allocated for core product development, vaccine registration, production capacity enhancement, working capital, and technology platform upgrades [1] Group 2 - The company is a China-based vaccine firm focused on innovative vaccines and the application of new technologies in traditional vaccine development, manufacturing, and commercialization [2] - The product pipeline includes two core products: a quadrivalent influenza virus subunit vaccine and an in-development freeze-dried human rabies vaccine, along with 11 other vaccines in research [2] - The company reported net losses of HKD 425 million for 2023, HKD 259 million for 2024, and HKD 87.31 million for the first quarter of 2025 [2]
中慧生物-B(02627.HK) 7月31日起招股